Lymphoma: How do we treat it? Where are future therapies headed?
Ann LaCasce, MD
On Wednesday, Dec. 18, Ann LaCasce, MD, of the Dana-Farber/Brigham and Women’s Cancer Center Adult Lymphoma Program will answer your questions about lymphoma care in a live video webchat. The 45-minute chat starts at 1 p.m. EST and will air live on Dana-Farber’s YouTube page.
LaCasce will discuss current treatment options as well as future therapies for lymphoma.
If you have a question for Dr. LaCasce, email firstname.lastname@example.org. You can also submit questions by sending us a Tweet @DanaFarber using the hashtag #DFCIWebchat.
Bookmark the webchat video page and tune in live on Dec. 18 at 1 p.m. EST. You can also add the event to your calendar or RSVP on Facebook.
Current lymphoma therapies are a far cry from the mustard gas used more than 50 years ago. More treatment options, including ones that may be more effective and less toxic, are being studied in ongoing clinical trials.
“Clinical trials really are the future of lymphoma treatment,” says Ann LaCasce, MD, a medical oncologist in the Adult Lymphoma Program at Dana-Farber/Brigham and Women’s Cancer Center.
More than 70 years ago, two pharmacologists began looking at mustard gas as a possible treatment for lymphoma. The chemical, used during World War I, lowered blood counts and destroyed lymph nodes in soldiers who were exposed to the gas.
Two decades after the war, a thoracic surgeon named Gustav Lindskog used nitrogen mustard to successfully treat a patient with non-Hodgkin’s lymphoma.
Craig Johnson (left) with stem donor Henrik Janssen
Their last names are practically identical. They are both fathers, and their oldest sons, now 6’3, were born on the same day – just two hours apart. “Blood brothers” Craig Johnson and Henrik Janssen had much to celebrate recently. Read more